Kevin W Gillman

This inventor holds 21 USPTO granted patents, plus 2 CIPO patents and 8 EPO patents, primarily in Immunomodulators. Top assignees: Bristol-Myers Squibb Compnay, Bristol Meyers Squibb Company. Active years: 2000-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kevin W Gillman. Retrieved from https://idiyas.com/inventor/kevin-w-gillman

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 21

% Patents Active = 95.2

CIPO Patents = 2

EPO Patents = 8 (Patent Applications = 10)

Average Co-Inventor Count = 4.3

ph-index = 5

Forward Citations = 45(Granted Patents)

Company Filing History:

20 out of 3,742

Bristol-Myers Squibb Compnay

patents

1 out of 41

Bristol Meyers Squibb Company

patents

Years Active: 2000-2024

Loading Chart...

Areas of Expertise:

Immunomodulators

PD-1 Antagonists

MGLUR5 Modulators

Beta Amyloid Inhibitors

CNS Disorders

Oxazolidinones

KCNQ Potassium Channels

Fluorooxindoles

Anorectic Agents

Heterocyclic Ethers

Sulfonamido Compounds

Carbohydrate Prodrugs

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11952434 - Immunomodulators (2024-04-09),

2. RE49735 - Oxazolidinones as modulators of MGLUR5 (2023-11-28),

3. 11358988 - Immunomodulators (2022-06-14),

4. 11066445 - Immunomodulators acting as antagonists of PD-1 (2021-07-20),

5. 10988507 - Immunomodulators (2021-04-27),

6. 10633419 - Immunomodulators (2020-04-28),

7. 10538555 - Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions (2020-01-21),

8. 9856292 - Immunomodulators (2018-01-02),

9. 8691821 - Oxazolidinones as modulators of mGluR5 (2014-04-08),

10. 8383821 - NK-1 and serotonin transporter inhibitors (2013-02-26),

11. 8350084 - Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production (2013-01-08),

12. 8093276 - Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production (2012-01-10),

13. 8084477 - Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production (2011-12-27),

14. 8071778 - Substituted heterocyclic ethers and their use in CNS disorders (2011-12-06),

15. 8044077 - Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production (2011-10-25),

Title: Kevin W Gillman: Innovator in Immunomodulation and CNS Treatment

Introduction

Kevin W Gillman, based in Madison, CT, is a prominent inventor with an impressive portfolio of 21 patents. His work primarily focuses on the development of compounds that have significant potential in the fields of immunology and neurology.

Latest Patents

Among his latest innovations, Gillman has developed immunomodulators that are designed for the treatment of various diseases, including cancer and infectious diseases. Additionally, he has worked on oxazolidinones as modulators of mGluR5, which includes compounds that act as ligands, agonists, and partial agonists for the mGluR5 receptor. These advancements may contribute to addressing various disorders of the central nervous system.

Career Highlights

Gillman's career includes notable tenures at Bristol-Myers Squibb Company, where he contributed significantly to pharmaceutical innovations. His expertise in his field is reflected in the patents he holds and the impact of his work on medical research and application.

Collaborations

Throughout his career, Gillman has collaborated with several distinguished professionals, including Paul Michael Scola and David R Langley. These collaborations have enriched his research and contributed to advancing the understanding of therapeutic compounds.

Conclusion

Kevin W Gillman's contributions to science and medicine through his inventions and patents highlight his role as a key innovator. His findings not only foster advancements in treatment possibilities but also serve as a foundation for future research and development in the medical field.

Profile summary based on public USPTO records.